You are here

Blueprint Medicines

FDA Grants Regular Approval of Gavreto for Metastatic NSCLC Subset

FDA Grants Regular Approval of Gavreto for Metastatic NSCLC Subset

Cure Today

Blueprint Medicines

non-small cell lung cancer

Flag link:

Roche pulls a Gavreto approval before Blueprint severance, citing unfeasible trial

Roche pulls a Gavreto approval before Blueprint severance, citing unfeasible trial

Fierce Pharma

Blueprint Medicines

accelerated approvals

Flag link:

What Will AbbVie Buy Next?

What Will AbbVie Buy Next?

Motley Fool

Blueprint Medicines

Krystal Biotech

Flag link:

Blueprint's Ayvakit picks up long-awaited FDA approval in indolent systemic mastocytosis

Blueprint's Ayvakit picks up long-awaited FDA approval in indolent systemic mastocytosis

Fierce Pharma

Blueprint Medicines

indolent systemic mastocytosis

systemic mastocytosis

Flag link:

FDA lifts partial hold on Blueprint's CDK2 inhibitor

FDA lifts partial hold on Blueprint's CDK2 inhibitor

Endpoints

Blueprint Medicines

Flag link:

Ahead of FDA decision, Blueprint puts out full data for expanded Ayvakit label

Ahead of FDA decision, Blueprint puts out full data for expanded Ayvakit label

Endpoints

Blueprint Medicines

systemic mastocytosis

Flag link:

Roche and Blueprint agree to end collaboration for cancer drug Gavreto

Roche and Blueprint agree to end collaboration for cancer drug Gavreto

Endpoints

Blueprint Medicines

Flag link:

Blueprint gears up for Ayvakit expansion, with blockbuster sales on the line

Blueprint gears up for Ayvakit expansion, with blockbuster sales on the line

Fierce Pharma

Blueprint Medicines

systemic mastocytosis

Flag link:

Blueprint drug succeeds in rare disease study important to its market prospects

Blueprint drug succeeds in rare disease study important to its market prospects

BioPharma Dive

Blueprint Medicines

systemic mastocytosis

clinical trials

Flag link:

Blueprint secures access to more than $1B in funding through two new deals

Blueprint secures access to more than $1B in funding through two new deals

BioPharma Dive

Blueprint Medicines

Flag link:

Riding success of Roche-partnered lung cancer drug, Blueprint makes $250M play for Lengo's preclinical work

Riding success of Roche-partnered lung cancer drug, Blueprint makes $250M play for Lengo's preclinical work

Fierce Biotech

Blueprint Medicines

Lengo Therapeutics

Flag link:

Scientific co-founder of Blueprint Medicines launches Recludix with $60M, 15-year Seagen exec steering the ship

Scientific co-founder of Blueprint Medicines launches Recludix with $60M, 15-year Seagen exec steering the ship

Fierce Biotech

Recludix Pharma

STAT inhibitors

Blueprint Medicines

Flag link:

Pfizer's CEO Wants to Go Shopping: 3 Potential Companies on His Radar

Pfizer's CEO Wants to Go Shopping: 3 Potential Companies on His Radar

Motley Fool

Blueprint Medicines

Aurinia Pharmaceuticals

Atea Pharmaceuticals

Flag link:

Rare Blood Disease Drug Win Marks Fourth Approval for Blueprint Medicines

Rare Blood Disease Drug Win Marks Fourth Approval for Blueprint Medicines

BioSpace

Blueprint Medicines

systemic mastocytosis

Flag link:

FDA Action Alert: Blueprint, Orphazyme and Eton

FDA Action Alert: Blueprint, Orphazyme and Eton

BioSpace

Blueprint Medicines

Eton Pharmaceuticals

Flag link:

Fortunes diverge for solo drug launchers

Fortunes diverge for solo drug launchers

EP Vantage

Intra-Cellular Therapies

Horizon Therapeutics

Karyopharm Therapeutics

Blueprint Medicines

Aurinia Pharmaceuticals

Global Blood Therapeutics

Flag link:

The Week Ahead In Biotech: FDA Decision On G1 Therapeutics, Earnings In The Mix For Light Calendar Week

The Week Ahead In Biotech: FDA Decision On G1 Therapeutics, Earnings In The Mix For Light Calendar Week

Yahoo/Benzinga

G1 Therapeutics

Blueprint Medicines

Ironwood Pharmaceuticals

Flag link:

Roche, Blueprint raise pressure on Lilly with new Gavreto approval

Roche, Blueprint raise pressure on Lilly with new Gavreto approval

Pharmaforum

Blueprint Medicines

Flag link:

Blueprint plots return to FDA with new Ayvakit data in rare condition — and the analysts cheer

Blueprint plots return to FDA with new Ayvakit data in rare condition — and the analysts cheer

Endpoints

Blueprint Medicines

Flag link:

Pages